Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $135 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Evogene (EVGN) click here.